Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.
[AIMS] Describe the characteristics, treatment patterns and outcomes of Chinese patients with unresectable advanced/metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA).
APA
Zhang J, Wang G, et al. (2025). Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.. Future oncology (London, England), 21(10), 1179-1188. https://doi.org/10.1080/14796694.2025.2476930
MLA
Zhang J, et al.. "Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.." Future oncology (London, England), vol. 21, no. 10, 2025, pp. 1179-1188.
PMID
40091795
Abstract
[AIMS] Describe the characteristics, treatment patterns and outcomes of Chinese patients with unresectable advanced/metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA).
[METHODS] This multicenter, retrospective, observational study included adults diagnosed with UAM GA/GEJA in China from 2017-2020.
[RESULTS] Among 2,745 patients, 1,902, 729, and 284 received first-, second- and third-line (1 L, 2 L and 3 L) therapy-respectively. Most patients received chemotherapy alone in 1 L (84.1%) and 2 L (63.6%), and targeted-therapy-based treatment in 3 L (49.2%). Median real-world progression-free survival (rwPFS) was 6.5, 4.2, and 3.2 months in 1 L, 2 L, and 3 L, respectively.
[CONCLUSIONS] Chinese patients with UAM GA/GEJA mainly received chemotherapy alone in 1 L/2 L and targeted therapy in 3 L. Median rwPFS was short in all lines, highlighting the need for more effective treatments.
[METHODS] This multicenter, retrospective, observational study included adults diagnosed with UAM GA/GEJA in China from 2017-2020.
[RESULTS] Among 2,745 patients, 1,902, 729, and 284 received first-, second- and third-line (1 L, 2 L and 3 L) therapy-respectively. Most patients received chemotherapy alone in 1 L (84.1%) and 2 L (63.6%), and targeted-therapy-based treatment in 3 L (49.2%). Median real-world progression-free survival (rwPFS) was 6.5, 4.2, and 3.2 months in 1 L, 2 L, and 3 L, respectively.
[CONCLUSIONS] Chinese patients with UAM GA/GEJA mainly received chemotherapy alone in 1 L/2 L and targeted therapy in 3 L. Median rwPFS was short in all lines, highlighting the need for more effective treatments.
MeSH Terms
Humans; Esophagogastric Junction; Stomach Neoplasms; Male; Female; Adenocarcinoma; Middle Aged; China; Retrospective Studies; Aged; Esophageal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Treatment Outcome; Neoplasm Staging; Aged, 80 and over; Molecular Targeted Therapy
같은 제1저자의 인용 많은 논문 (5)
- Mitochondria in situ releasing corosolic acid enhanced antitumor effects via activating mitophagy in castration-resistant prostate cancer.
- [Exploring the intervention mechanism of modified Danggui buxue decoction on neuroinflammation in CIPN model mice based on transcriptomics and network pharmacology].
- Injectable HMME-Loading Emulsion Hydrogel for Ultrasound-Triggered Release and Enhanced Sonodynamic Immunotherapy.
- Bilaterality in papillary thyroid carcinoma: long-term outcomes and predictive factors.
- Identification of a 9-gene autophagy-related signature for predicting prognosis and immune exhaustion features in breast cancer.